反応式
Br[CH2:2][C:3]1[NH:8][C:7]([C:9]2[S:10][CH:11]=[CH:12][N:13]=2)=[N:6][CH:5]([C:14]2[CH:19]=[CH:18][C:17]([Cl:20])=[CH:16][C:15]=2[Cl:21])[C:4]=1[C:22]([O:24][CH2:25][CH3:26])=[O:23].[NH:27]1[CH2:32][CH2:31][O:30][CH2:29][CH:28]1[C:33]([NH2:35])=[O:34]>>[C:33]([CH:28]1[N:27]([CH2:2][C:3]2[NH:8][C:7]([C:9]3[S:10][CH:11]=[CH:12][N:13]=3)=[N:6][CH:5]([C:14]3[CH:19]=[CH:18][C:17]([Cl:20])=[CH:16][C:15]=3[Cl:21])[C:4]=2[C:22]([O:24][CH2:25][CH3:26])=[O:23])[CH2:32][CH2:31][O:30][CH2:29]1)(=[O:34])[NH2:35]参加物
3
実験手順
Ethyl 6-(bromomethyl)-4-(2,4-dichlorophenyl)-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate (2.85 g, 6 mmol) was reacted with morpholine-3-carboxamide (0.78 g, 6 mmol) according to the procedure as described in Example 25, Step B to give the title compound as a yellow solid (1.54 g, 49%). The compound was characterized by the following spectroscopic data:
出典と根拠
- ORDレコード
- ord-004aecd12c014c4e9bb133c6582e3fe3
- 出典データセット
- uspto-grants-2016_05
- 特許番号
- US09340538B2
関連ノート
読み込み中…